Global Industry Analysts, Inc., Sep 2008, Pages: 321
, and Medimmune 86
Table 18: Leading Products in the US Biotechnology Market
(2006): Sales in US$ Million for Aranesp, Epogen, Enbrei,
Neulast, Procrit, Remicade, Rituxan, Avastin, Lantus, and
Herceptin 87
Decision Resources, Inc., Nov 2006, Pages: 26
Choose to Go to the Moon”
Companies to Watch
It Will Be Done in This Decade
Tables
1. Ranking of Monoclonal Antibodies by Indication and WorldwideSales
2. Select Companion Diagnostic Tests
Figures
Informa Healthcare, Oct 2008, Pages: 12
The world’s first biotechnology company, Genentech, was founded in 1976. 30 years later there were 4,275 biotechnology companies worldwide, of which 710 were publicly listed. This Scrip analysis
Global Industry Analysts, Inc., Feb 2011, Pages: 682
This report analyzes the worldwide markets for Angiogenesis Inhibitors and Stimulators in US$ Million by the following product segments - Angiogenesis Inhibitors, and Angiogenesis Stimulators
Research In China, July 2011, Pages: 64
of Available Monoclonal Antibody Drugs
3.5.4 Active R&D
4. Market Segments in China
4.1 Rituxan
4.2 Herceptin
4.3 Erbitux
4.4 Nimotuzumab
4.5 Etanercept
5. Key Manufacturers Worldwide
5.1 Roche
5
Research In China, July 2011, Pages: 64
of Available Monoclonal Antibody Drugs
3.5.4 Active R&D
4. Market Segments in China
4.1 Rituxan
4.2 Herceptin
4.3 Erbitux
4.4 Nimotuzumab
4.5 Etanercept
5. Key Manufacturers Worldwide
5.1 Roche
5
Global Industry Analysts, Inc., Oct 2006, Pages: 563
: Global Sales of Herceptin: 1999-2006 (US$
Million) (includes corresponding Graph/Chart) II-16
Competitive Factors II-16
2. Product Overview II-17
History in a Nutshell II-17
Anatomy of the Breast II
Decision Resources, Inc., March 2008, Pages: 39
of the global pharmaceutical market, with worldwidesales of almost $30 billion in 2006. What factors account for the success of this fast growing market? How is the pharmaceutical industry responding
TriMark Publications, June 2009, Pages: 112
of sales in the U.S. and worldwide, and it analyzes the factors that influence the size and the growth of the market segments. The study goes on to discuss in detail the trends that have developed which have
Global Industry Analysts, Inc., Sep 2011, Pages: 794
This report analyzes the worldwide markets for Companion Diagnostics in US$ Thousand. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual
Decision Resources, Inc., June 2006, Pages: 28
on Drug Development Costs
Figure 5 Rapidly Increasing Use of Pharmacogenomics Information in New Drug Labels, 1945-2005
Figure 6 Worldwide Projected Sales of Trastuzumab (Herceptin), 2005-2010 (millions
Decision Resources, Inc., Dec 2009, Pages: 34
Indications
3. Roche’s Targeted Cancer Therapies Pipeline
4. Pfizer’s Targeted Cancer Therapies Pipeline
5. Merck & Co.’s Targeted Cancer Therapies Pipeline
6. WorldwideSales of Leading Targeted Cancer
Global Industry Analysts, Inc., Oct 2011, Pages: 897
that have attained blockbuster status and sales of these drugs continue to rise with each passing year. Factors such as increasing number of new and overall cancer patients worldwide, as well as the relative
Arrowhead Publishers, Aug 2008, Pages: 318
Therapies
6.8 Financial Forecast
7 The Breast Cancer Therapy Market
7.1 Current Treatment of Breast Cancer
7.1.1 Surgery
7.1.2 Radiation Therapy
7.1.3 Hormonal Therapy
7.1.4 Cytotoxics
7.1.5 Herceptin
7
Decision Resources, Inc., April 2008, Pages: 28
in 2001 for CMS, boasts sales of $3 billion worldwide in 2007.
What effect has Gleevec’s success had on the development of new kinase inhibitors?
-Most major pharmaceutical companies are avidly pursuing
Global Industry Analysts, Inc., Oct 2008, Pages: 527
: Leading Players in the Worldwide Monoclonal
Antibody Therapy Market (2005): Percentage Breakdown of
Sales for Genentech/Roche, J & J/Schering Plough, Abbott
Laboratories, Med
TriMark Publications, Jan 2011, Pages: 1679
volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including
TriMark Publications, Jan 2011, Pages: 156
NIH Research Budget, 1995-2010 19
Table 2.12: HerceptinWorldwideSales, 2000-2015 20
Table 2.13: Classes of Drugs Used to Treat Breast Cancer 20
Table 2.14: Women's Cancers in the U.S., 2010 21
Table 2
